Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

BUY
$7.12 - $20.24 $44,236 - $125,751
6,213 Added 10.58%
64,945 $1.3 Million
Q2 2022

Aug 11, 2022

BUY
$5.1 - $10.0 $77,428 - $151,820
15,182 Added 34.86%
58,732 $405,000
Q1 2022

May 12, 2022

SELL
$8.34 - $14.69 $11,450 - $20,169
-1,373 Reduced 3.06%
43,550 $405,000
Q4 2021

Feb 10, 2022

BUY
$13.6 - $24.89 $7,235 - $13,241
532 Added 1.2%
44,923 $639,000
Q3 2021

Nov 12, 2021

BUY
$21.22 - $25.7 $39,787 - $48,187
1,875 Added 4.41%
44,391 $1.03 Million
Q2 2021

Aug 05, 2021

BUY
$22.86 - $30.95 $255,483 - $345,897
11,176 Added 35.66%
42,516 $1.06 Million
Q1 2021

May 06, 2021

BUY
$24.58 - $42.82 $282,817 - $492,686
11,506 Added 58.01%
31,340 $878,000
Q4 2020

Feb 10, 2021

BUY
$34.9 - $51.08 $76,814 - $112,427
2,201 Added 12.48%
19,834 $692,000
Q3 2020

Nov 12, 2020

BUY
$32.95 - $50.25 $581,007 - $886,058
17,633 New
17,633 $879,000

Others Institutions Holding FMTX

About Forma Therapeutics Holdings, Inc.


  • Ticker FMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,860,400
  • Market Cap $958M
  • Description
  • Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...
More about FMTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.